CytRx (CYTR) is out with more data in support of aldoxorubicin efficacy.
The "additional statistical analyses" of the Phase 2b study determined the hazard ratios on the PFS endpoint: HR for investigator-read scans, 0.37; HR for central lab scans, 0.59.
The company also says a Kaplan-Meier analysis "showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin." (PR)
For the originally reported results, see here.
CYTR +10% premarket